✦ LIBER ✦

Monitoring liver safety in drug development: The GSK experience

✍ Scribed by Christine M. Hunt; Julie I. Papay; Rita I. Edwards; Dickens Theodore; David H. Alpers; Colin Dollery; Tjerk W. DeBruin; Kimberly K. Adkison; Heide A. Stirnadel; Trevor G. Gibbs

Book ID: 113965215
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 295 KB
Volume: 49
Category: Article
ISSN: 0273-2300
DOI: 10.1016/j.yrtph.2007.06.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Molecular clinical safety intelligence:

Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery – the GSK experience

✍ Dana E. Vanderwall; Nancy Yuen; Mohammad Al-Ansari; James Bailey; David Fram; Da 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 976 KB

Drug Safety Sciences and the Bottleneck

Drug Safety Sciences and the Bottleneck in Drug Development

✍ Watkins, P B 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 176 KB

The Safety Risks of InnovationThe FDA's

The Safety Risks of InnovationThe FDA's Expedited Drug Development PathwayThe Safety Risks of Innovation in Drug Development

✍ Moore, Thomas J. 📂 Article 📅 2012 🏛 American Medical Association 🌐 English ⚖ 50 KB

The discovery and development of proteom

The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity

✍ David E. Amacher 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 224 KB

The use of pharmacokinetic and pharmacod

The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development

✍ D. K. Walker 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB

Developing a culture of safety in the ep

Developing a culture of safety in the epilepsy monitoring unit: A retrospective study of safety outcomes

✍ Spanaki, Marianna V.; McCloskey, Cathleen; Remedio, Virginia; Budzyn, D.; Guanio 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 288 KB